ReviewFrontiers in medicine2025
A bibliometric analysis of targeted therapy cardiotoxicity research in cancer patients (2004-2024).
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The management of long-term cardiotoxicity has become increasingly challenging despite the growing utilization of targeted therapies to enhance progression-free and overall survival rates. Although there is a proliferation of literature on the incidence and mechanisms of cardiotoxicity induced by targeted therapies, no comprehensive analysis of the publication landscape has addressed the unmet medical needs in this area. This study aimed to characterize global research trends, map collaborative networks, and highlight unresolved issues in cardiotoxicity management to fill the gaps in this field and inform future research. Method: This study conducted a bibliometric analysis of articles concerning targeted therapy-induced cardiotoxicity published between 2004 and 2024 from the Web of Science (WOS) database using VOSviewer and CiteSpace. A total of 1,054 publications from 71 countries/regions and 2,058 research institutions were examined. Result: The number of publications has shown an average annual increase of 50 articles from 2004 to 2024. Key research topics in targeted therapy cardiotoxicity encompass breast cancer, heart failure, and drug delivery. The most cited publication is a guideline titled "Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline." These results indicate a rising trend in research on tumor-targeted therapy cardiotoxicity over the past two decades. Recent research trends and future directions primarily focus on two key areas: the development of novel nanocarriers aims to enhance therapeutic efficacy while reducing cardiac toxicity, and the exploration of mechanisms underlying cardiac injury caused by targeted therapeutic drugs is crucial, along with the investigates drug interventions to counter these mechanisms or the application of alternative techniques for the prevention, alleviation, or treatment of cardiac injury. Conclusion: This study provides a comprehensive overview of targeted therapy-induced cardiotoxicity research from 2004 to 2024. By identifying key research priorities, this analysis addresses critical gaps in current knowledge. Future endeavors should prioritize translational innovations and multidisciplinary clinical frameworks to enhance therapeutic safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.